Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally advanced setting or with chemotherapy in first-line...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Med
Autors principals: Leblanc, Olivia, Vacher, Sophie, Lecerf, Charlotte, Jeannot, Emmanuelle, Klijanienko, Jerzy, Berger, Frédérique, Hoffmann, Caroline, Calugaru, Valentin, Badois, Nathalie, Chilles, Anne, Lesnik, Maria, Krhili, Samar, Bieche, Ivan, Le Tourneau, Christophe, Kamal, Maud
Format: Artigo
Idioma:Inglês
Publicat: Compuscript 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7142836/
https://ncbi.nlm.nih.gov/pubmed/32296588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2019.0153
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars